(Q50510640)

English

FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy.

scientific article published in August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. (English)

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Spencer Williams

6

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

7

object named as

Henry Krum

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

8

object named as

Darren J Kelly

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

2

object named as

Yuan Zhang

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

author name string

Sih Min Tan

1

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Bing Wang

3

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Christina Y R Tan

4

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Steven C Zammit

5

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

publication date

1 August 2012

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Clinical and Experimental Pharmacology and Physiology

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

39

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

8

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

650-656

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Diabetes mellitus and cardiac function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

IL-6 switches the differentiation of monocytes from dendritic cells to macrophages

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Current perspectives in diastolic dysfunction and diastolic heart failure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Role of macrophages in complications of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05726.X

21 January 2018

Identifiers

10.1111/J.1440-1681.2012.05726.X

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22612418

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50510640&oldid=1307450725"